What we had seen with the weakness last month. Overnight in asia, the nikkei actually was down almost 1 . The shanghai was up by a half percent. In europe you will see the dax is flat. So is the ftse cac is up. There are green arrows across the complex of stocks. The treasury markets this morning will be closely watched. The tenyear at this point is yielding above 2 . We want to start with some developing news. The New York Times reporting that President Trump approved military strikes on targets in iran that would be in retaliation for shooting down a surveillance drone but the mission was called off at the last minute eamon javers joins us in washington, d. C. With the latest good morning. The New York Times and the Washington Post are reporting that the president authorized these air strikes last night but backed off at some point subsequent to having authorized it the New York Times is reporting that the mission was under way. There were planes in the air, but missiles had not been
Weight loss drug trial and we look at one business segment critical to growing the economy but unaffordable for many child care the ceo of Bright Horizons joins us with the stock up more than 45 so far this year first, though, lets talk about the market dom chu has the numbers. Down and in the red if you look at the picture overall, were hovering towards the lower end of the trading range. The dow is down about 290 points or three quarters of 1 to the downside the s p 500, the broader measure of the market, up 4479, down 39 points, or about nearly 1 , as well you can see there just for context, its been a down day overall. At the highs, we were still down 20 points and down 54 at the lows ill call your attention to just one number, were not really there yet. But watch 4421 some traders are talking about that as a target that they are watching right now, the 50day moving average for the s p 500 we havent been towards these levels since going back to the memorial day holiday, around that
Competitors to emerge. This is how pharmaceutical companies are moving, into the sort of Lifestyle Drugs to help bring up their revenues for the next few years. Help bring up their revenues for the next few veere next few years. Looking at the numbers. Next few years. Looking at the numbers. They next few years. Looking at the numbers, they are next few years. Looking at the i numbers, they are astronomical. Taking market value to 428 billion, dethroning even lvmh. Give us a sense of its rise, but because it is a company that most people wouldnt heard of. A company that most people wouldnt heard of. ,. , heard of. Yes, it is. There arent that many heard of. Yes, it is. There arent that many world heard of. Yes, it is. There arent that many world famous heard of. Yes, it is. There arent that many world famous danish | that many world famous danish companies, either. It is a sector thatis companies, either. It is a sector that is becoming more and more important. Increasing affluence ar
Arrangement, and are you guaranteeing what is the price of the drug when are you saying you are only going to get paid x if you reach a cure level or certain level of adherence. Theres some interference there, and its used as an excuse for those types of arrangement or getting out of those arrangements by pharmaceutical companies. The other is the fda approves the drug if it works. And they dont necessarily approve it saying whether it works better than things that have previously been approved or whether it doesnt work better than thing previously approved. And that can create some friction when it comes to dealing with providers who seem to want to gravitate toward the newest and the latest, even if it really doesnt turn out to work any better than some of the alternatives that have come down the pike before. So whats the solution there . More as we heard on the earlier panel, more effectiveness, information and data . I think the comparative effectiveness would really help. Then you
And coming up, more on the recent health and Human Services forum on pharmaceutical innovation and drug costs. Up next, senators from medicare and medicaid acting administrator andy slavit and purchasing strategies for the pharmaceutical industries. This includes manufacturers, employers, consumers, Health Insurance providers and government officials. Once again, if you will all take your seats well get started on the final panel of the day. Where as promised, well devote our discussion to outcomes based purchasing, what is the potential for those, what are the obstacles and how do we get to better value and better accessibility for patients as soon as possible through these and other mechanisms. Let me introduce our panelists now. You have been introduced to at least this gentleman there, dan durham, Senior Vice President of ahib, thats americas Health Insurance plans. And ken frazier is with us, the president and chief executive officer of merck and company. One of the premier pharma